Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9876492 | 0.84 | PTPN11 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3506718 | 0.78 | NOTUM (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31144878 | 0.78 | NOTUM (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29893239 | 0.76 | CFTR (0.50) | NOTUMCFTRPTPN11LMNAKDM4E | |
| SCHEMBL14252071 | 0.76 | CFTR (0.56) | NOTUMCFTRPTPN11EGLN1KDM4E | |
| SCHEMBL385370 | 0.74 | LMNA (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12669342 | 0.74 | KIF11 (0.64) | EGLN1CYP1A1CYP1B1PTGS1LMNA | |
| SCHEMBL672493 | 0.74 | KIF11 (0.64) | EGLN1CYP1A1CYP1B1PTGS1LMNA | |
| SCHEMBL20031375 | 0.74 | CA1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31710343 | 0.73 | CFTR (0.56) | NOTUMCFTRPTPN11MRGPRX4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353161-B1 | TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS | US HEALTH (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10683277-B2 | Triazole derivatives as P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683277-B2 | Triazole derivatives as P2Y14 receptor antagonists | GPR119, P2RY14, P2RY4 | CA12 4817/4885CA1 4636/4885CA2 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.